Longitude Capital

Longitude Capital

Longitude Capital was founded in 2006 by Patrick Enright and Juliet Tammenoms Bakker, two veterans of the life sciences investment ecosystem. Enright previously spent over a decade at Pequot Ventures, where he built the healthcare practice, while Tammenoms Bakker had covered medical devices and diagnostics at ABN AMRO and later served as a managing director at Pequot. The firm emerged not as a generalist technology investor dabbling in healthcare, but as a dedicated platform for translating biomedical innovation into clinical and commercial reality. The co-founders structured the firm around a physician-operator model: each investment professional has deep sector training, and the partnership actively recruits operating advisors from pharma, medtech, and payer organizations. Longitude deploys capital across four distinct healthcare verticals: biotechnology, medical devices, healthcare services, and digital health. On the biotech side, the firm is stage-agnostic within private companies, entering as early as preclinical platform formation and following through crossover rounds. Known portfolio positions include involvement with gene editing platform Intellia Therapeutics, fibrosis-focused Pliant Therapeutics, and oncology developer Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in 2022. In medical devices, Longitude has backed structural heart innovator Ancora Heart (acquired by Edwards Lifesciences) and transcatheter valve developer JenaValve. The healthcare services book reflects an operational bent — the firm targets specialty provider groups, tech-enabled care delivery, and value-based care enablement. Geographical focus is primarily North America, though the firm has selectively invested in European biotech platforms with US commercialization pathways. Longitude closed its fourth flagship fund in 2022 at approximately $1.2B (per the firm's official communications), bringing aggregate capital raised across all vehicles to more than $3.4B. The firm maintains an investment office in Greenwich, Connecticut in addition to its Menlo Park headquarters. While Longitude does not operate a public philanthropic foundation, the co-founders are active in biomedical advisory roles — Enright serves on the board of the Spinal Muscular Atrophy Foundation, a rare disease research organization. The firm has never marketed a multi-family office or club-deal vehicle; all capital has been raised through traditional limited partner commitments from institutional allocators. Recent activity includes the deployment of Fund IV into clinical-stage precision medicine companies, continuing the firm's established rhythm of two to three new platform investments per year. Structurally, Longitude occupies a deliberately narrow bandwidth. The firm avoids medtech products that require hospital capital-equipment sales forces, does not invest in phase-III assets without a differentiated mechanism of action, and has never raised a generalist technology fund. This enforced specialization creates a sourcing advantage — management teams and university tech-transfer offices route biomedical opportunities to Longitude before they reach multi-sector platforms. Succession remains partner-led; Enright and Tammenoms Bakker are active managing directors, and the next layer of investment leadership includes senior principals who have been with the firm for over a decade. For institutional allocators building dedicated healthcare allocations, Longitude functions as a pure-play alternative to life sciences teams embedded within larger multi-asset managers.